Management Profiles

Dr. Peter Watson


Dr. Peter Watson is Director of the Tumor Tissue Repository Program at the BC Cancer Agency, an agency of the Provincial Health Services Authority (PHSA) in British Columbia. He also holds appointments as the Chief Physician Vancouver Island Centre, Senior Scientist and a Professor of Pathology, University of British Columbia, and academic positions at the University of Victoria and University of Manitoba.
He completed his medical training at the University of Cambridge and St Thomas's Hospital London, UK in 1983 and specialist training in Anatomic Pathology at the University of Manitoba in 1988. After fellowship training he established a career as a clinician scientist in 1993 at the University of Manitoba, and since 2005 at the BC Cancer Agency.

He currently combines a clinical practice as a breast pathologist with research interests in the molecular pathology of breast and ovarian cancer, and in the discipline of biobanking. His research program focuses on biomarkers of breast tumour progression and response to therapies. This work has included the discovery, validation, elucidation of the mechanism of action, and exploration of the therapeutic potential of the S100A7 gene in breast cancer. This research has led to publication of over 150 scientific research papers.

He has also lead provincial and national biobanking initiatives to advance translational cancer research. In addition, Dr. Watson serves on the executive of the Canadian Tumour Repository Network (CTRNet) he is currently the director of the University of British Columbia, Department of Pathology Office of Biobank Education and Research, co-leads the Manitoba Breast Tumor Bank and serves on the executive of the Marble Arch International Working Group for Biobanking.

Dr. Anne-Marie Mes-Masson


Dr. Anne-Marie Mes-Masson is a molecular oncologist who obtained her degree in microbiology and immunology from McGill University in 1984. From 1984 to 1986, she pursued her post-doctoral studies at UCLA's Molecular Biology Institute, researching the BCR-ABL gene implicated in chronic myelogenous leukemia. She was then appointed as a research associate at the Biotechnology Research Institute in Montreal. In 1989, Dr. Mes-Masson joined the Montreal Cancer Institute, and the University of Montreal's department of medicine, where she became a full professor in 2001.

Presently, Dr. Mes-Masson acts as Scientific Director of the Montreal Cancer Institute and is responsible for oncology research at the University of Montreal's teaching hospital (Centre de recherche du CHUM). She also serves on the executive of CTRNet. In 2003, Dr. Mes-Masson was nominated as director of the Cancer Research Network (Réseau de recherche sur le cancer RRCancer) for the Fonds de la recherche en santé du Québec's (FRSQ).Dr. Mes-Masson's research focuses on the development of cancer models and on the identification of molecular events implicated in ovarian and prostate cancer, and their translation into clinical tools for patient management.

Canadian Tissue Repository Network (CTRNet) Management:

View full profiles of CTRNet Management